Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2010-10-08
2011-11-29
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100
Reexamination Certificate
active
08067003
ABSTRACT:
Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
REFERENCES:
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5210075 (1993-05-01), Scholz et al.
patent: 5326859 (1994-07-01), Sugano et al.
patent: 5468609 (1995-11-01), Revel et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5554513 (1996-09-01), Revel et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
patent: 5618700 (1997-04-01), Novick et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5639455 (1997-06-01), Shimanura et al.
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5738931 (1998-04-01), Sato et al.
patent: 5789552 (1998-08-01), Savino et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5817790 (1998-10-01), Tsuchiya et al.
patent: 5849283 (1998-12-01), Ciliberto
patent: 5854398 (1998-12-01), Chang et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5914106 (1999-06-01), Ciliberto
patent: 5942220 (1999-08-01), Warren et al.
patent: 5958400 (1999-09-01), Ruben et al.
patent: 5972902 (1999-10-01), Ciliberto
patent: 6010864 (2000-01-01), Hoeprich, Jr.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6121423 (2000-09-01), Tsuchiya et al.
patent: 6261560 (2001-07-01), Tsujinake et al.
patent: 6461604 (2002-10-01), Somers et al.
patent: 6482411 (2002-11-01), Ahuja et al.
patent: 7291721 (2007-11-01), Giles-Komar et al.
patent: 2001/0001663 (2001-05-01), Kishimoto et al.
patent: 2003/0190316 (2003-10-01), Kakuta et al.
patent: 2004/0028681 (2004-02-01), Ito et al.
patent: 0399429 (1990-11-01), None
patent: 0572118 (1993-04-01), None
patent: 0617126 (1994-09-01), None
patent: 800829 (1997-10-01), None
patent: WO 91/08774 (1991-06-01), None
patent: WO 94/09138 (1994-04-01), None
patent: WO 95/03036 (1995-02-01), None
patent: WO 01/58956 (2001-08-01), None
patent: WO 03/083061 (2003-10-01), None
patent: WO 2004/039826 (2004-05-01), None
patent: WO 2004/096273 (2004-11-01), None
patent: WO 2005/005604 (2005-01-01), None
patent: WO 2005/028514 (2005-03-01), None
US 6,008,005, 12/1999, Shiraki et al. (withdrawn)
Brakenhoff, et al., “Structure-Function Analysis of Human IL-6 Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino- and Carboxyl-Terminal Deletion Mutants,” The Journal of Immunology, 145(2): 561-568 (1990).
Brakenhoff, et al., “Molecular Cloning and Expression of Hybridoma Growth Factor inEscherichia coli,” The Journal of Immunology, 139(12): 4116-4121 (1987).
Van Zaanen, et al., Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp130, Leukemia & Lymphoma, 31 (5-6): 551-558 (1998).
Van Zaanen, et al., Endogenous Interleukin 6 Production in Multiple Myeloma Patients Treated with Chimeric Monoclonal Anti-IL6 Antibodies Indicates the Existence of a Positive Feed-back Loop, Journal of Clinical Investigations, The American Society for Clinical Investigation, Inc., 98(6): 1441-1448 (1996).
Van Oers, Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study, British Journal of Haematology, 102(3): 783-790 (1998).
Baselga, et al., “Receptor Blockage with Monoclonal Antibodies as Anti-Cancer Therapy,” Pharmaceutical Therapy, 64: 127-154 (1994).
Matsuda, et al., “Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies,” European Journal of Immunology, 18: 951-956 (1988).
Seideman, et al., “A novel monoclonal antibody screening method using the Luminex-100 microsphere system,” Journal of Immunology Methods, 267: 165-171 (2002).
Bataille, et al., Biologica Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma, Blood, 86(2): 685-691 (1995).
Trikha, et al., “Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence,” Clinical Cancer Res., 9: 4653-4665 (2003).
Sato, et al., “Humanization of an Anti-Human IL-6 Mouse Monoclonal Antibody Glycosylated in its Heavy Chain Variable Region,” Human Antibodies and Hybridomas, 7(4): 175-183 (1996).
Naka, et al., “The Paradigm of IL-6: From Basic Science to Medicine,” Arthritis Research, Current Science, 4(3): S233-S242 (2002).
Petrov, “Immunology,” Medicine Publishers, 56-58 (1987), Russian Article and English translation.
Paul, “Fv Structure and Diversity in Three Dimensions,” Fundamental Immunology, 3rdedition pp. 292-295 (1993).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Science, USA 79: 1979-1783 (1982).
Cruse and Lewis, Illustrated Dictionary of Immunology, p. 19 (1995).
Aoki, et al., “Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6,” Blood, 93(12): 4034-4043 (1999).
Pourtau, et al., “Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M,” FEBS Letters, 459: 453-457 (1999).
Wei, et al., “Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway,” Oncogene, 22:1517-1527 (2003).
Motro, et al., “Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis,” Proceedings of the National Academy of Science USA, 87: 3092-3096 (1990).
Cohen, et al., “Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor,” The Journal of Biological Chemistry, 271(2): 736-741 (1996).
Chauhan, et al., “SHP2 Mediates the Protective Effect of Interleukin-6 against Dexamethasone-induced Apoptosis in Multiple Myeloma Cells,” The Journal of Biological Chemistry, 275(36): 27845-27850 (2000).
Blay, et al., “Serum Level of Interleukin 6 as a Prognosis Factor in Metastic Renal Cell Carcinoma,” Cancer Research, 52: 3317-3322 (1992).
Miki, et al., “Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas,” FEBS Letters, 250(2): 607-610 (1989).
Vink, et al., Mouse Plasmacytoma Growth in Vivo: Enhancement by Interleukin 6 (IL-6) and Inhibition by Antibodies Directed against IL-6 or Its Receptor, Journal of Experimental Medicine, 172: 997-1000 (1990).
Sato, et al., “Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth,” Cancer Research, 53: 851-856 (1993).
Shimamura, et al., “Analysis of Interleukin-6 (IL-6)/IL-6 Receptor System Using Monoclonal Anti-IL-6 Antibodies,” Molecular Immunology, 28(11): 1155-1161 (1991).
Chen Yan
Gardner Debra
Knight David M.
Lark Michael W.
Liang Bailin
Applied Molecular Evolution, Inc.
Centocor, Inc.
Dichter Eric
Mertz Prema
LandOfFree
Methods of treating conditions using anti-IL-6 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating conditions using anti-IL-6 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating conditions using anti-IL-6 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286046